Arterial Device-Focused Inari Medical Likely Acquisition Target, Shares Are Attractively Valued: Analyst
Arterial Device-Focused Inari Medical Likely Acquisition Target, Shares Are Attractively Valued: Analyst
Needham initiated coverage on Inari Medical Inc (NASDAQ:NARI), noting it as a leader in the very large and underpenetrated market for venous thrombectomy.
尼德姆開始對Inari Medical Inc（納斯達克股票代碼：NARI）進行報道，指出該公司在龐大且滲透率不足的靜脈血栓切除術市場中處於領先地位。
Inari Medical projects an annual patient population of 280,000 with pulmonary embolism (PE) in the U.S., equating to a total available market (TAM) of $2.8 billion for its FlowTriever product.
Inari Medical預計，美國每年的肺栓塞（PE）患者人數爲28萬人，相當於其FlowTriever產品的總可用市場（TAM）爲28億美元。
Additionally, the company estimates a yearly count of 430,000 patients with deep vein thrombosis (DVT), resulting in a $3.0 billion TAM for its ClotTriever product. The penetration rates for the PE and DVT markets are approximately 20% and 15%, respectively.
此外，該公司估計，每年有43萬名深靜脈血栓形成（DVT）患者，從而使其ClotTriever產品的TAM達到30億美元。私募股權和DVT市場的滲透率分別約爲20％和15％。
Needham initiates with a Buy rating and a price target of $72.
Needham最初的評級爲買入，目標股價爲72美元。
In late 2023, Inari Medical acquired LimFlow SA for $250 million in cash at closing and is eligible to receive up to $165 million in additional payments based on certain commercial and reimbursement milestones, for a total potential transaction value of up to $415 million.
2023年底，Inari Medical在收盤時以2.5億美元現金收購了LimFlow SA，根據某些商業和報銷里程碑，有資格獲得高達1.65億美元的額外付款，潛在交易總額高達4.15億美元。
The analyst writes that Inari Medical presents a compelling acquisition opportunity.
該分析師寫道，Inari Medical提供了一個引人注目的收購機會。
The company aligns with the criteria sought by major medical technology firms, boasting a robust gross margin of approximately 88%, anticipated double-digit revenue growth (projected at around 19% CAGR from 2023 to 2026), and a revenue size approaching $500 million in 2023.
該公司符合主要醫療技術公司尋求的標準，毛利率約爲88％，預計將實現兩位數的收入增長（預計從2023年到2026年複合年增長率約爲19％），2023年的收入規模接近5億美元。
Furthermore, Inari Medical holds a prominent position in the high-growth venous thrombectomy segment.
此外，Inari Medical在高生長的靜脈血栓切除術領域佔據突出地位。
Needham identifies potential suitors for acquisition, including Abbott Laboratories Inc (NYSE:ABT), Becton, Dickinson And Co (NYSE:BDX), Boston Scientific Corporation (NYSE:BSX), Medtronic Plc (NYSE:MDT), Koninklijke Philips N.V. (NYSE:PHG), Stryker Corp (NYSE:SYK), Teleflex Inc (NYSE:TFX), and Terumo Corp (OTC:TRUMF) (OTC:TRUMY).
尼德姆確定了潛在的收購者，包括雅培實驗室公司（紐約證券交易所代碼：ABT）、Becton、Dickinson And Co（紐約證券交易所代碼：BDX）、波士頓科學公司（紐約證券交易所代碼：BSX）、美敦力集團（紐約證券交易所代碼：MDT）、Koninklijke Philips N.V.（紐約證券交易所代碼：PHG）、Stryker Corp（紐約證券交易所代碼：SYK）、泰利福公司（紐約證券交易所代碼：SYK）、泰利福公司（紐約證券交易所代碼：SYK）（紐約證券交易所代碼：SYK）、泰利福公司（紐約證券交易所代碼：SSE: TFX）和Terumo Corp（場外交易代碼：TRUMF）（場外交易代碼：TRUMY）。
Needham writes that Inari Medical shares are attractively valued, trading at 5.1x its estimated sales for 2024, showing a 21% premium compared to similar small/mid-cap growth companies with a median estimated EV/S multiple of 4.2x.
尼德姆寫道，Inari Medical的股票估值極具吸引力，其2024年預計銷售額爲5.1倍，與類似的中小型成長型公司相比，溢價了21％，估計EV/S倍數中位數爲4.2倍。
Additionally, Inari Medical shares exhibit a 9% premium compared to small/mid-cap companies in the cardiovascular and neuromodulation sector, with a median estimated EV/S multiple of 4.7x.
此外，與心血管和神經調節領域的中小型股公司相比，Inari Medical的股票溢價爲9％，估計的EV/S倍數中位數爲4.7倍。
Price Action: NARI shares are down 0.27% at $57.40 on the last check Tuesday.
價格走勢：在週二的最後一次支票中，NARI股價下跌0.27％，至57.40美元。
譯文內容由第三人軟體翻譯。